Search - tctmd.com

Displaying 61 - 80 of 406

Sort: Relevancy | Date

News Conference News NY Valves 2024

National Data Point to Soaring TAVI Rates in Patients Under 65

Michael O'Riordan

June 14, 2024

News Conference News NY Valves 2024

Dedicated Devices for Aortic Regurgitation Supported by Meta-analysis

Todd Neale

June 13, 2024

News Conference News NY Valves 2024

Good 3-Year Outcomes With Aortic Valve-in-Valve Replacement for Failed SAVR

Michael O'Riordan

June 11, 2024

Presentation NY Valves 2024

SAVR Transaxillary Approach: Pushing the Boundaries

Presenter: Joerg Kempfert

June 07, 2024

Presentation NY Valves 2024

Transaxillary Non-Robotic SAVR – Yet Another Option

Presenter: Joerg Kempfert

June 06, 2024

Presentation NY Valves 2024

BASILICA or ShortCut for TAV-in-SAVR or TAV-in-TAV

Presenter: Philippe Genereux

June 06, 2024

Presentation NY Valves 2024

SAVR is Clearly the Gold Standard in AS Patients Under 65 Years Old

Presenter: Keith B. Allen

June 06, 2024

Presentation NY Valves 2024

SAVR After TAVR: A Dangerous Epidemic?

Presenter: Shinichi Fukuhara

June 06, 2024

Presentation NY Valves 2024

Why Favor Redo SAVR After a Failed Bioprosthetic AVR?

Presenter: Tsuyoshi Kaneko

June 06, 2024

Presentation NY Valves 2024

SAVR Will Have a Longer Lasting Durability Than TAVR

Presenter: Stephan Windecker

June 06, 2024

Presentation NY Valves 2024

Determinants of Intervention Type and All-Cause Mortality of TAVR and SAVR Patients Younger Than 75 Years in the Netherlands

Presenter: Nicolas M. Van Mieghem

June 06, 2024

Presentation NY Valves 2024

TAVR Will Have a Longer Lasting Durability Than SAVR

Presenter: Michael J. Reardon

June 06, 2024

Presentation NY Valves 2024

Cases 3/4 : SAVR at 10 Years and SVD at 2 Years: Echo and Clinical

Presenter: Mark Lebehn

June 06, 2024

Presentation NY Valves 2024

A Randomized Comparison of TAVR and SAVR in Low-Risk Patients Aged 70 Years or Younger: Results From the NOTION-2 Trial

Presenter: Ole De Backer

June 05, 2024

News Daily News

Patient Decision Aid Improves Shared Decision-making in Aortic Stenosis

Yael L. Maxwell

May 28, 2024

News Conference News EuroPCR 2024

TAVI, Surgery Look Similar Long-term Across Risk Spectrum: Meta-analysis

Michael O'Riordan

May 16, 2024

News Conference News EuroPCR 2024

Young, Low-risk Patients Fare Well With TAVI, but Beware the Bicuspids

Michael O'Riordan

May 15, 2024

Presentation EuroPCR 2024

First TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis - results from NOTION-2

Presenter: Ole De Backer

May 15, 2024

News Conference News EuroPCR 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Michael O'Riordan

May 14, 2024

News Conference News

TAVI Use Rising in Young US Patients, Yet Another Analysis Shows

Yael L. Maxwell

May 06, 2024

Advertisement

National Data Point to Soaring TAVI Rates in Patients Under 65

Dedicated Devices for Aortic Regurgitation Supported by Meta-analysis

Good 3-Year Outcomes With Aortic Valve-in-Valve Replacement for Failed SAVR

SAVR Transaxillary Approach: Pushing the Boundaries

Transaxillary Non-Robotic SAVR – Yet Another Option

BASILICA or ShortCut for TAV-in-SAVR or TAV-in-TAV

SAVR is Clearly the Gold Standard in AS Patients Under 65 Years Old

SAVR After TAVR: A Dangerous Epidemic?

Why Favor Redo SAVR After a Failed Bioprosthetic AVR?

SAVR Will Have a Longer Lasting Durability Than TAVR

Determinants of Intervention Type and All-Cause Mortality of TAVR and SAVR Patients Younger Than 75 Years in the Netherlands

TAVR Will Have a Longer Lasting Durability Than SAVR

Cases 3/4 : SAVR at 10 Years and SVD at 2 Years: Echo and Clinical

A Randomized Comparison of TAVR and SAVR in Low-Risk Patients Aged 70 Years or Younger: Results From the NOTION-2 Trial

Patient Decision Aid Improves Shared Decision-making in Aortic Stenosis

TAVI, Surgery Look Similar Long-term Across Risk Spectrum: Meta-analysis

Young, Low-risk Patients Fare Well With TAVI, but Beware the Bicuspids

First TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid aortic valve stenosis - results from NOTION-2

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

TAVI Use Rising in Young US Patients, Yet Another Analysis Shows

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content